{"id":"W4224138250","doi":"10.1182/bloodadvances.2021006434","title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia ","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Hazard ratio; Adverse effect; Oncology; Confidence interval; Leukemia; Gastroenterology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002472379,0.0006561411,0.001707131,0.0006124551,0.0009711698,0.001054651,0.000611423,0.00122119,0.002617664],"category_scores_gemma":[0.003530589,0.0003010009,0.001680652,0.0005373245,0.0003835275,0.001182446,0.00112567,0.002285273,0.0008554033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007960469,"about_ca_system_score_gemma":0.0006112352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001755162,"about_ca_topic_score_gemma":0.002593437,"domain_scores_codex":[0.9990693,0.0002674515,0.00008372154,0.0001866923,0.0001556293,0.0002371767],"domain_scores_gemma":[0.9967213,0.0007560984,0.000765833,0.0003670178,0.0004507133,0.0009390733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2248743,0.005273222,0.5464643,0.0007813183,0.003510076,0.002608471,0.0006500144,0.003351319,0.008932834,0.000261476,0.01160098,0.1916919],"study_design_scores_gemma":[0.01309447,0.05591973,0.9020588,0.0001923526,0.004438086,0.001764063,0.0002115977,0.001333788,0.003010732,0.0005388398,0.01730367,0.0001337708],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719786,0.008548208,0.001000292,0.0005272393,0.0001300108,0.0005451738,0.01174254,0.00009392605,0.005434043],"genre_scores_gemma":[0.974075,0.001214128,0.0004518749,0.0007901881,0.0001393786,0.0005153986,0.01993717,0.00002341175,0.002853457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002617664,"threshold_uncertainty_score":0.01307541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01781755912526684,"score_gpt":0.2833469322780211,"score_spread":0.2655293731527543,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}